Refine your search:     
Report No.
 - 

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with $$^{64}$$Cu-labeled trastuzumab PET

Paudyal, P.*; Paudyal, B.*; Hanaoka, Hirofumi*; Oriuchi, Noboru*; Iida, Yasuhiko*; Yoshioka, Hiroki*; Tominaga, Hideyuki*; Watanabe, Satoshi; Watanabe, Shigeki; Ishioka, Noriko; Endo, Keigo*

Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of $$^{64}$$Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with $$^{64}$$Cu-DOTA-trastuzumab. PET studies revealed a significantly high accumulation of $$^{64}$$Cu-DOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 h and 48 h post-injection. $$^{64}$$Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy.

Accesses

:

- Accesses

InCites™

:

Percentile:67.02

Category:Oncology

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.